Cytomegalovirus Complicating Biological Immunosuppressive Therapy in Two Patients with Psoriasis Receiving Treatment with Etanercept or Efalizumab

By Petersen Bibi   Lorentzen Henrik  

Acta Dermato-Venereologica, Vol. 88, Iss. 5, 2008-09 ,pp. : 523-524

Medical Journals Limited

Access to resources Recommend Favorite

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies

By Driessen Rieke   Boezeman Jan   Van De Kerkhof Peter   De Jong Elke  

Journal of Dermatological Treatment, Vol. 20, Iss. 1, 2009-02 ,pp. : 42-47

Informa Healthcare

Access to resources Recommend Favorite

Addition of Pentoxifylline Could Reduce the Side Effects of Fumaric Acid Esters in the Treatment of Psoriasis

By Friedrich Markus   Sterry Wolfram   Renérückert Anja Klein   Döcke Wolf Dietrich   Asadullah Khusru  

Acta Dermato-Venereologica, Vol. 81, Iss. 6, 2001-12 ,pp. : 429-430

Medical Journals Limited

Access to resources Recommend Favorite

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

By Papp Kim   Ho Vincent   Langley Richard   Lynde Charles   Poulin Yves   Shear Neil   Toole John   Zip Catherine  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 26-32

Springer Publishing Company

Access to resources Recommend Favorite

ILVEN: Is it Psoriasis? Debate Based on Successful Treatment with Etanercept

By Renner Regina   Colsman Andreas   Sticherling Michael  

Acta Dermato-Venereologica, Vol. 88, Iss. 6, 2008-11 ,pp. : 631-632

Medical Journals Limited

Access to resources Recommend Favorite